FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Peptide Compounding Pharmacy Physician Prescribed Peptides Massey Drugs BREAKING: FDA UPDATES CATEGORY 2 BULKS LIST OFFICIALLY REMOVES PEPTIDES LIKE BPC 157 The first opportunity for reclassification comes on July 23 24 during the FDA's PCAC meeting Until then, peptides are